| Filed On | Filing |
|---|---|
| 30 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing. |
| 28 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
The undersigned, Actuate Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Regis... |
| 17 Jul 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing. |
| 22 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 21, 2026, Actuate Therapeutics, Inc. (the “Company”) hosted its Annual Meeting of Stockholders (“Annual Meeting”) virtually. At the Annual Meeting, the Company's stockholders (i) elected each of the two Class II director nominees ... |
| 11 May 2026 |
8-K: Regulation FD Disclosure
This presentation contains forward - looking statements about us, including our clinical trials and development plans, and our industry, that are based on management’s beliefs and assumptions and on information currently available to our... |
| 06 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone |
| 28 Nov 2025 |
8-K: Entry into a Material Definitive Agreement
Actuate Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with B. Riley Securities, Inc. (“B. Riley Securities”) and Craig-Hallum Capital Group LLC (“Craig-Hallum”) (each of B. Riley Se... |
| 21 Nov 2025 |
8-K: Other Events
Actuate Therapeutics’ investors and others should note that we announce material information to the public about our company and its technologies, clinical and corporate developments, and other matters through a variety of means, includi... |
| 10 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Actuate Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Lucid Capital Markets, LLC (the “Underwriter”) an aggregate of 2,142,858 authorized but... |
| 26 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 25, 2025, by and among Actuate Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement ... |
| 05 Jun 2025 |
8-K: Regulation FD Disclosure
Link to access replay: https://lifescievents.com/event/actuate/ |
| 02 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
This presentation contains forward - looking statements about us, including our clinical trials and development plans, and our industry, that are based on management’s beliefs and assumptions and on information currently available to our... |
| 23 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 22, 2025, Actuate Therapeutics, Inc. (the “Company”) hosted its Annual Meeting of Stockholders (“Annual Meeting”) virtually. At the Annual Meeting, the Company's stockholders (i) elected each of the three Class I director nominees... |
| 06 May 2025 |
8-K: Other Events
Topline data shows statistically significant improvement in overall survival in elraglusib plus GnP combination arm versus GnP control arm |
| 28 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of March 27, 2025 (this “Agreement”), by and between B. Riley Principal Capital II, LLC, a Delaware limited liability company (the “Investor”), and Actuate Therapeutics, In... |
| 07 Feb 2025 |
8-K: Other Events
Actuate Therapeutics, Inc. (the “Company”) will host its first Annual Meeting of Stockholders (“Annual Meeting”) virtually on May 22, 2025. The Company’s Board of Directors also set a record date of March 25, 2025, entitling stockholders... |
| 17 Dec 2024 |
8-K: Regulation FD Disclosure
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer |
| 12 Nov 2024 |
8-K: Regulation FD Disclosure
Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumr |
| 19 Aug 2024 |
8-K: Changes in Registrant's Certifying Accountant
We have read the comments made regarding us in Item 4.01 of Form 8-K of Actuate Therapeutics, Inc. dated August 19, 2024, and are in agreement with those statements. |
Loading...